AnaptysBio, Inc., a clinical-stage biotechnology company focused on immunology therapeutics, has released its Q3 2024 report, showcasing financial growth and advancements in its clinical-stage programs. The company is progressing its pipeline with key data readouts expected in the near future.
Financial Performance
AnaptysBio reported a substantial increase in collaboration revenue, reaching $30.0 million for the three months ended September 30, 2024, compared to $3.3 million for the same period in 2023. The loss from operations decreased to $(22.8) million from $(37.7) million year-over-year. Research and development expenses increased to $42.2 million, reflecting the company's commitment to advancing its pipeline.
Clinical Pipeline Advancements
AnaptysBio's pipeline includes rosnilimab (PD-1 agonist) in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032 (BTLA agonist) in a Phase 2b trial for atopic dermatitis. Enrollment is complete for the Phase 2b trial of rosnilimab in rheumatoid arthritis, with top-line data expected in February 2025. The Phase 2 trial for ulcerative colitis is ongoing, with data expected in Q1 2026. ANB032 has completed enrollment for its Phase 2b trial in atopic dermatitis, with top-line data anticipated in December 2024.
"We are focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases," the company stated in its report.
New Product Development
ANB101, a BDCA2 modulator antibody, is set to begin a Phase 1 clinical trial in Q1 2025. This product targets plasmacytoid dendritic cells, which are implicated in autoimmune and inflammatory diseases. AnaptysBio has entered into an exclusive license agreement with Centessa Pharmaceuticals for the development of BDCA2 modulator antibodies, including ANB101 and ANB102, for autoimmune and inflammatory diseases.
Collaborative Programs and Regulatory Milestones
AnaptysBio has multiple antibody programs under collaboration, including an immuno-oncology collaboration with GSK. Jemperli (dostarlimab) has received multiple FDA and EMA approvals for various cancer indications and is in ongoing clinical trials for additional indications. Jemperli received FDA approval in July 2023 for use in combination with chemotherapy for endometrial cancer, and the EMA approved this combination in December 2023.
GSK is developing dostarlimab in combination with cobolimab (anti-TIM-3 antibody) in a Phase 3 trial for non-small-cell lung cancer, with top-line results expected in the first half of 2025.
Strategic Initiatives and Future Outlook
AnaptysBio plans to out-license imsidolimab, an IL-36R antagonist, in 2024 following successful Phase 3 trials for generalized pustular psoriasis. The company is also seeking a licensing partner for etokimab, an IL-33 antagonist. AnaptysBio completed an underwritten public offering in August 2024, raising approximately $93.9 million in net proceeds, and has a sales agreement with TD Securities (USA) LLC to offer and sell shares of its common stock, having an aggregate offering of up to $100.0 million.
The company is exploring additional financing and strategic investments to support its ongoing and planned clinical trials and to further develop its product candidates.
